This web only provides the extract of this article. If you want to read the figures and tables, please reference the PDF full text on Blackwell Synergy. Thank you.
- Complementary Medicine -
Ex vivo antioxidant effects of D-004, a lipid extract from
Roystonea regia fruits, on rat prostate tissue
Yohani Pérez, Vivian Molina, Rosa Mas, Roberto Menéndez, Rosa M. González, Ambar Oyarzábal, Sonia Jiménez
Laboratory of Biochemistry, Center of Natural Products, National Center for Scientific Research, Havana City 6990, Cuba
Abstract
Aim: To investigate whether oral treatment with D-004, a lipid extract of the Cuban
royal palm fruit, produces antioxidant effects in the prostate tissue of normal and testosterone (T)-treated
rats. Methods: In our first experiment, normal rats were distributed into five groups: one group treated with the vehicle and four groups treated with D-004
(100, 200, 400 or 800 mg/kg). In our second experiment, rats were randomized into five groups: a negative control
group and four T-injected groups. The latter were comprised of a positive control group treated with the vehicle, and
three groups treated with D-004 (200, 400 or 800 mg/kg).
Results: In normal rats, D-004 (100_800 mg/kg)
inhibited significantly and dose-dependently iron-initiated malondialdehyde (MDA) accumulation in prostate homogenates
(35.7%_80.0%) vs. the controls. D-004 (200_800 mg/kg) significantly reduced baseline MDA and carbonyl groups
in prostate homogenates of normal rats to approximately 80% and 50%, respectively, and totally (100%) in T-treated
rats. Conclusion: Oral treatment with
D-004 reduced MDA and carbonyl groups dose-dependently and markedly in
normal and T-injected rats. These findings show that D-004 given at doses effective to prevent prostate hyperplasia
also produces antioxidant effects in the prostate tissue.
(Asian J Androl 2008 Jul; 10: 659_666)
Keywords: D-004; Roystonea regia; Cuban royal palm; prostate hyperplasia; lipid peroxidation; antioxidant
Correspondence to: Dr Yohani Pérez, Laboratory of Biochemistry, Center of Natural Products, National Center for Scientific Research,
Havana City 6990, Cuba.
Tel: +53-7-2714-200 Fax: +53-7-2736-837
E-mail: yohani.perez@cnic.edu.cu
Received 2007-08-23 Accepted 2007-12-14
DOI: 10.1111/j.1745-7262.2008.00385.x
1 Introduction
Benign prostate hyperplasia (BPH), a common disease
in older men, is the non-malignant and uncontrolled growth
of the prostate gland that could lead to urethral obstruction
and to lower urinary tract symptoms (LUTS) [1].
The hormonal changes in the aging man, such as the
increased conversion of testosterone (T) in
dihydrotestosterone (DHT), catalyzed by prostate
5α-reductase, is pivotal in triggering BPH as increased prostate DHT
concentrations promote excessive cellular growth,
causing hyperplasia [2]. Therefore, prostate
5α-reductase inhibitors are widely used to treat BPH, decreasing the
size of the enlarged prostate and modestly improving
LUTS [3]. BPH also involves non-hormonal factors, such
as the increased α1-adrenergic tone of prostate smooth
muscle [4]. α1-Adrenoreceptor blockers are also
indicated to treat BPH, improving mainly the symptoms [5].
However, the link between BPH and oxidative stress
(OS) is limited. Cooperative function of antioxidant and
redox systems against OS in male reproductive tissues
has been reported [6]. It has been shown that OS plays
a role in testes and fertility impairment [7,
8], and it might play a role in prostate cancer [9], but its influence in
BPH has not been proven. However, some evidence does
suggest that OS might be associated with BPH [9, 10].
Serum protein-bound sialic acid levels, a
marker of prostate growth, and lipid peroxides are higher in men with
BPH than in controls, but lower than in men with
prostate cancer, and it has been hipothesized that OS might
be linked to the extent of protein sialylation in both
pathological conditions [9].
In addition, the fact that an extract from cactus
flower inhibited 5α-reductase activity and displayed
antioxidant effects in rat prostate homogenates [10], and
that the androgenic regulation of OS during rat prostate
involution and regrowth involves the antioxidant
defensive enzyme system [12], suggests links between OS
and BPH. Likewise, T (5 mg/kg, subcutaneously) has
raised OS in rat prostate, an effect prevented by giving
black tea extracts for 15 days [13]. Similar effects were
found in mice injected with T and treated with diallyl
sulphide for 7 days. In positive control mice,
antioxidant enzyme levels lowered and lipid peroxidation (LP)
markers increased in prostate and liver, and diallyl
sulphide restored the T-induced antioxidant enzymes and
LP in both organs [14]. Also, oral treatment with saw
palmetto lipid extract (100 mg/kg) reduced prostate
enlargement, lipid hydroperoxides, and glutathione
peroxidase activity in rats with hyperprolactinemia-induced
prostate hyperplasia (PH) [10].
D-004 is a lipid extract from Cuban royal palm
(Roystonea regia) fruits containing a mixture of free fatty
acids: oleic, lauric, palmitic, and myristic acids are the
most abundant; and caprylic, capric, palmitoleic, stearic,
linoleic, and linolenic acids are in lower concentrations.
Mature fruits of R. regia, initially dried and ground, are
submitted to alkaline hydrolysis and to a further selective
extraction with n-hexane for obtaining this extract.
D-004 competitively inhibits prostate 5α-reductase
in vitro [15] and, given orally, prevents PH induced with T [16],
not with DHT [17], in rodents. D-004 has been shown
to reduce prostate enlargement and the histological
changes of prostate induced with T in rats observed in
the positive controls, such as the presence of irregular
acinis with intraluminal projections, focal conglomerate
of cells into the acinis and stroma, and stroma
hyperplasia and hypertrophy of fibrocytes and smooth muscle
cells, assessed with a score-chart protocol. Samples from
D-004-treated rats had flattened epithelial cells, regular,
unfolded acini, and delicate stroma intermingled between
the acini, similar to the pattern found in negative controls
[16]. In addition, D-004 antagonizes
α1-adrenoreceptor-mediated responses [18, 19].
D-004 has shown to inhibit in vitro the iron-induced
malondialdehyde (MDA) generation in prostate homogenates [20], and metal and non-metal-induced LP in rat
brain and liver microsomes ex vivo in a dose-dependent
manner [21]. Assuming a link between increased OS and
BPH, the potential ability of oral treatment with
D-004 to prevent prostate LP should be relevant to manage this
condition, but such effect has not yet been reported.
In light of these facts, this study investigated whether
oral treatment with D-004 produces "ex
vivo" antioxidant effects in the prostate tissue of normal and T-treated
rats.
2 Materials and methods
2.1 Animals
All experiments were approved by the Institutional
Board of Animal Care and Use at the Center of Natural
Products (National Center for Scientific Research,
Havana City, Cuba). Young adult male Wistar rats
(180_200 g) were housed two per cage and food (rodent chow)
(EMO 1002) supplied by Centre for Laboratory Animals
Production (CENPALAB, Havana City, Cuba) and tap water were available
ad libitum. Room lights were on from 07:00 to 19:00, the room temperature was
25 ± 3ºC, and the relative humidity was
60% ± 5%.
2.2 Materials
All chemicals were purchased from Sigma-Aldrich
(St. Louis, MO, USA) and the Ultrospec-Plus
spectrophotometer was from Pharmacia LKB Biotechnology
(Uppsala, Sweden).
2.3 Treatment methods and dosage
The batch of D-004 was obtained from the Chemistry Department of the Center of Natural Products, its
composition and purity being assessed with a validated
gas chromatography method. The free fatty acid
composition (w/w) of the tested batch was: caprylic 0.8%,
capric 1.0%, lauric 30.2%, myristic 10.4%, palmitic
7.7%, palmitoleic 0.2%, stearic 2.2%, oleic 29.7%,
linoleic 9.5%, and linolenic 0.1%. The purity (as the total content of
free fatty acids) was 91.8%. Results complied with
substance specifications. D-004 was suspended in
Tween-65/H2O (2%). Suspensions were prepared daily, 1 h
before use.
Two experiments were carried out, the first in
normal rats (150_200 g), and the second in rats
(200_250 g) with T-induced PH. In the first experiment, normal rats
were randomized into five groups (10 rats/group)
comprising a control group treated with the vehicle and four
groups treated with D-004 (100, 200, 400 or 800 mg/kg),
doses at which D-004 had been shown to be effective in
inhibiting LP in rat plasma, liver and brain tissues
[21].
In the second experiment, rats were randomized into
five groups (10 rats/group) comprising a negative
control group, treated with the vehicle, and four T-injected
groups. The latter included a positive control group,
treated with the vehicle only, and three groups treated
with D-004 at 200, 400, or 800 mg/kg. In this experiment,
testosterone-propionate (Cuban Medical Pharmaceutical
Industry, Havana City, Cuba) was diluted in soy oil and
injected subcutaneously (3 mg/kg) for 2 weeks to induce
PH in the rats, as previously described, and the doses of
D-004 assessed were those that had resulted in effective
prevention of T-induced PH in rodents [16].
In both experiments, treatments (vehicle or D-004)
were given by gastric gavage through the oral route (1 mL/rat),
once daily, in the morning (08:00_10:00), 6 days a week,
for 2 weeks.
Bodyweight was controlled the day before starting
the treatments and weekly thereafter.
The day after treatment completion, after 12-h
overnight fasting, rats were anesthetized under ether
atmosphere. Prostates were immediately removed and
weighed. The whole organs were taken for LP studies.
2.4 LP assays
LP in prostate homogenates was estimated by measuring baseline or iron-initiated MDA concentrations [22].
Aliquots of whole prostate tissue (200 mg) were taken
and gently homogenized in 9 volumes of 150 mmol/L
Tris/HCl buffer (pH 7.4), in an ice-cold bath, with an
Ultra-Turrax homogenizer (model T25; Janke & Kunkel GMBH
& CO.KG IKA Labortechnik, Staufen, Germany). The
reaction mixture was treated with 0.2 mL of 8.1%
sodium dodecyl sulfate, 1.5 mL of acetic acid 20% (pH
3.5), and 1.5 mL of thiobarbituric acid 0.8%, and heated to
95ºC for 1 h. Then 50 μL butylated hydroxytoluene
(1 mmol/L) was added, samples were cooled, and
5 ml of an n-butanol:piridine (15:1 v/v) mixture was added,
stirring vigorously with a vortex, and centrifuged at 1 600 ×
g for 20 min. The organic layer was taken and the optical
density measured at 534 nm (final volume 1 mL, protein
concentration 500 μg/mL).
MDA concentrations were determined from a standard curve of malondialdehyde bis-(dimethyl acetal) and
reported as nmol MDA/mg protein. Protein
concentration was assessed through a modification of the Lowry
method [23]. The LP in prostate homogenates was
initiated by adding a 2 µmol/L
FeCl3/200 µmol Adenosine 5'-Diphosphate complex and 200 µmol/L
β Nicotinamide adenine dinucleotide phosphate reduced tetrasodium salt
[24]. All assays were carried out in triplicate.
2.5 Effects on protein oxidation
Protein oxidation was assayed through the
dinitrophenylhydrazine (DNPH) assay [25]. In brief, prostate
aliquots (200 g) were homogenized in 3 mL of phosphate
buffer 50 mmol/L (pH 7.4), containing digitonin 0.1%
and 40 μg/mL of a mixture of protease inhibitors and
Ethylenediaminetetraacetic acid 1 mmol/L, centrifuged at
6 000 × g for 15 min, and the optical density of the
supernatant measured at 280/260 nm to discard the
presence of nucleic acids. As no value was greater than 1,
the addition of streptomycin sulphate 1% to eliminate
nucleic acids was not necessary. The supernatant (1 mL)
was added to 4 mL DNPH 10 mmol/L dissolved in HCl
2.5 mol/L, and the mixture was stirred vigorously and
placed in the dark. After 1 h, 5 mL trichloroacetic
acid (10%) was added, and the mixture centrifuged at
1 000 × g for 15 min. The protein pellet was washed
three times with a mixture of ethanol:ethyl acetate (1:1,
v/v) to eliminate the excess DNPH. The protein pellet
was dissolved in 2 mL guanidine 6 mol/L. Optical
density measured at 450 nm, using a 22
000 mol_1 coefficient of molar extinction, and the concentration of
carbonyl groups was reported in nmol/mg protein. The
protein concentration was assessed as above [22].
Determinations were carried out in triplicate.
2.6 Statistical analysis
Data were expressed as the mean ± SE. For
statistical analysis of data, the non-parametric Kruskal-Wallis
test was used to compare differences among groups,
and the Mann_Whitney U-test for paired comparisons
between control and treated groups. The level of
statistical significance was set at α = 0.05, multiplicity being
adjusted to P < 0.0125 for the results of the
Kruskal-Wallis test. All analyses were carried out using Statistics
software for Windows (Release 6.0; StatSoft, Tulsa, OK,
USA).
3 Results
Table 1 summarizes the effect of oral treatment with
D-004 on MDA accumulation in prostate homogenates of normal rats. D-004 (100_800 mg/kg) significantly
inhibited iron-initiated LP, assessed through prostate
accumulation of MDA, compared with the controls, from
35.7% (100 mg/kg) to approximately 80%. The
maximum effect was achieved with 400 mg/kg, as
800 mg/kg did not produce a greater inhibition.
Table 2 shows the effects of D-004 on rats with
T-induced PH. D-004 (100_800 mg/kg) did not affect
bodyweight gain with respect to the positive controls
(data not shown). D-004 at 400 and 800 mg/kg, but not
at 200 mg/kg, significantly prevented the increase of both
prostate weight and prostate weight/bodyweight ratio
induced with T. In this experiment, the effect of D-004
increased abruptly with the dose, as 200 mg/kg was not
effective, reducing prostate enlargement by only 8.1%
compared with the positive control, whereas D-400 at
400 and 800 mg/kg produced complete inhibition.
The baseline MDA values in prostate homogenates
of the positive controls were greater than in the
negative controls (Table 3). D-004 markedly reduced baseline
MDA levels in prostate tissue of both normal and
T-treated rats in a dose-dependent manner. In normal
rats, the reduction induced with 200 mg/kg was not
significant comapproximately 80.0% (83.6% with 400 mg/kg, 84.8% with 800 mg/kg); therefore,
400 mg/kg seems to produce the ceiling effect on this marker too.
Likewise, D-004 (200_800 mg/kg) significantly
lowered baseline values of MDA in prostates of T-treated
rats with respect to the positive controls, although in
this case the inhibition was complete (100%) and greater
than in normal rats.
Table 4 lists the effects of D-004 on protein-linked
carbonyl groups. D-004 (200_800 mg/kg), but not at
100 mg/kg, significantly reduced the content of carbonyl
groups in prostate homogenates from normal rats. The
effects were dose-dependent, but moderate, as the
inhibitions achieved with 400 and 800 mg/kg were 51.6%
and 54.8%, respectively. In turn, D-004
(200_800 mg/kg) significantly reduced the carbonyl groups in prostate
homogenates from T-treated rats. A complete inhibition (100%) was reached with 400 mg/kg, whereas
the effect of 200 mg/kg, although significant, was
lower than that observed in prostate homogenates from
normal rats.
4 Discussion
This study shows that oral treatment with D-004
at doses from 100 to 800 mg/kg given for 2 weeks
produced marked and dose-dependent antioxidant effects on prostate tissue of normal rats and of rats with
PH induced with T. Although the preventive effects
of D-004 on PH induced with T had already been reported [26], this effect was re-assessed in this study to
corroborate that the effects of D-004 on OS
markers of T-treated rats were produced
with the same doses of D-004 and in the same group of rats with manifested
prostate enlargement.
Although D-004 has been shown to prevent LP in rat
plasma, liver and brain [21], the effects on OS markers
in the prostate, the presumed target of any potential
benefit on PH, had not been studied. Considering this fact,
and also that serum lipid peroxides have been shown to
be useful to predict OS in tissues [27], we investigated
here the effects of oral dosing with D-004 on OS
markers in rat prostate.
The antioxidant ability of D-004 on prostate tissue
was investigated in rats with normal and hypertrophied
prostates, this last condition being potentially more
representative of human prostates with BPH. Although the
effects on OS can be assayed by examining the extent of
LP, protein oxidation, and oxidative DNA damage, here
we only investigated the effects of D-004 on LP and
protein oxidation in rat prostate through changes in
baseline and iron-induced accumulation of MDA levels,
a marker routinely used for LP [28], and the
concentration of carbonyl groups, a marker of protein oxidation
[28]. OS acts on many biological targets, but lipid
molecules are among the most involved, and LP gives rise
to a number of secondary products, MDA being the most
studied marker of polyunsaturated fatty acid (PUFA)
peroxidation [25]. In turn, the oxidative damage of
proteins occurs concomitantly to the increase in the number
of carbonyl residues that can be assayed by
the stable hydrazone derivatives formed with DNPH
[25].
The iron-induced MDA accumulation in prostate homogenates of normal rats reflects the tissue response
to metal-elicited LP, a condition that was markedly
(approximately 80%) inhibited with D-004. The effects
were dose-dependent and the maximal inhibition
(approximately 80%) was achieved with 400 mg/kg.
Consistent with previous data, D-004 (400 and 800 mg/kg) significantly prevented T-induced prostate
enlargement without affecting bodyweight gain [26]. In
a previous study, however, D-004 at 200 mg/kg had been
effective in this model [17], but in the present study this
dose only produced a negligible effect (8.1% inhibition).
Nevertheless, doubling the dose of D-004 to 400 mg/kg
produced complete inhibition (100%). This result
supports the view that the antioxidant effects of D-004 on
the prostate tissue of T-treated rats, reported here, were
obtained in rats with evident prostate enlargement.
The increased MDA and carbonyl levels in the
prostate of positive control rats indicate that T induces
peroxidative reactions in lipids and proteins, and that
D-004 prevented against this injury induced with T. The
content of carbonyl groups in prostate homogenates of
control normal rats was similar to that of the negative
controls of the experiment in T-treated rats, and the MDA
values of the latter were higher, probably due to the fact
that the rat body weight in the second experiment was
greater and baseline MDA levels in rat plasma or tissues
could be affected by this factor, something observed in
our historical data.
Despite the fact that D-004 was able to prevent
LP and protein oxidation in prostate homogenates of
both normal and T-treated rats, the antioxidant
effects in T-enlarged prostates were greater than in the normal
ones. In the case of baseline MDA levels, this difference
was moderate, as the maximal effects in normal rats were
marked (approximately 80%), whereas in T-treated rats
the inhibition was complete (100%). Nevertheless, the
differences regarding the reduction of carbonyl groups
were actually noticeable, as the inhibition achieved in
normal rats was moderate (approximately 50%), whereas
the inhibition in prostates of T-treated rats was twice
that in normal rats, and complete (100%). These
results suggest that in conditions of increased tissue OS,
as occurs in enlarged prostates, the preventive
effects of D-004 on peroxidative processes are greater than in
normal conditions, and that such difference is
remarkable in the case of protein oxidation.
Patients with BPH have been shown to have increased
blood LP and decreased antioxidant enzymes, like
superoxide dismutase [29]. In light of this issue, the
possibility that the antioxidant effects of D-004 on rat prostate
could involve the enhancement of the antioxidant enzymes
can not be discarded, but such effects were not assessed
in this study. The present results, therefore, merit
further research into the mechanisms of the antioxidant
effects of D-004 on normal and enlarged rat prostates,
including its potential effects on antioxidant enzymes.
The fractions and extracts from Prunus africana
bark, commonly used to treat BPH, which contain high
levels of myristic acid, one of the most abundant fatty
acids in D-004, have been shown to potently inhibit
ferrous ion-induced stimulation of LP in microsomal
preparations from rabbit livers [30]. In consequence, the
antioxidant effects of D-004 could be associated at least in
part to this compound, although we have not found
specific reports of the effects of such acid on LP in prostate
tissue.
The doses of D-004 that prevented LP in prostate
homogenates were similar to those reported in liver
microsomes, but greater than those required to inhibit
LP in brain microsomes, in which D-004 at 100 mg/kg
already produced maximal inhibition [21]. Although the
lipid nature of D-004 constituents could suppose a
preferential distribution into the brain, a previous study found
a fast and broad radioactivity distribution in rats 2 h after
dosing with (3H)-labelled oleic acid mixed in D-004
(400 mg/kg), the values in prostate being higher than in
tissues and plasma [31], consistent with the efficacy of
D-004. Consistent with these results, the magnitude of
the antioxidant effect of D-004 on several markers here
studied was ¡Ý 80%, particularly in the hypertrophied
prostate where the inhibition was complete. The doses
required to inhibit OS markers in prostate tissue are greater
than those required to inhibit LP in brain microsomes.
This apparent discrepancy in the potency of D-004 in
prostate tissue vs. brain tissue requires further explanation.
Previous data showed that D-004 prevents PH induced with T in rodents, with an efficacy similar to that
of saw palmetto extracts [16], indicating that D-004 could
be promising to treat BPH. The mechanisms involved in
the effects of D-004 include the inhibition of the
5α-reductase enzyme [15] and the antagonism of responses
mediated by α1-adrenergic receptors [18, 19]. The fact
that D-004 given at doses that prevent PH can display
antioxidant effects on prostate tissue could represent an
additional benefit, but this assumption requires not only
the assessment of the effects of D-004 on other parameters
of OS, such as total peroxides and antioxidant enzymes, in
prostate tissue, but also increased evidence of the role of
OS in human BPH.
The present results, together with the negligible
toxicity of D-004 indicated in toxicological studies, support
the benefits in continuing studies on this substance as a
potential new phytotherapeutic agent to manage BPH.
However, confirmation of this assumption still requires
extensive clinical research.
References
1 Bhargava S, Canda AE, Chapple CR. A rational approach to
benign prostatic hyperplasia evaluation: recent advances. Curr
Opin Urol 2004; 14: 2_6.
2 Carson C, Rittmaster R. The role of dihydrotestosterone in
benign prostatic hyperplasia. Urology 2003; 61 (Suppl 1): 2_7.
3 Sandhu JS, Te AE. The role of 5 alpha-reductase inhibition as
monotherapy in view of the MTOPS data. Curr Urol Rep
2004; 5: 274_9.
4 Michel MC, Taguchi K, Schafers RS. α1-Adrenoceptors
subtypes in the human cardiovascular and urogenital systems.
Adv Pharmacol 1998; 42: 394_8.
5 Oelke M, Höfner K, Berges RR, Jonas U. [Drug therapy of
benign prostatic hyperplasia syndrome with alpha 1-
receptors blockers. Basic principles and clinical results.] Urologe A
2002; 41: 425_41.
6 Fujii J, Iuchi Y, Matsuki S, Ishii T. Cooperative function of
antioxidant and redox systems against oxidative stress in male
reproductive tissues. Asian J Androl 2003; 5: 231_42.
7 Armagan A, Uz E, Ramazan H, Soyupek S, Oksay T, Ozcelik
N. Effects of melatonin on lipid peroxidation and antioxidant
enzymes in streptozotocin-induced diabetic rat testis. Asian J
Androl 2006; 8: 595_600.
8 Zhou DX, Qiu SD, Zhang J, Tian H, Wang HX. The
protective effect of vitamin E against oxidative damage caused by
formaldehyde in the testes of adult rats. Asian J Androl 2006;
8: 584_8.
9 Goswami K, Nandeesha H, Koner BC, Nandakumar DN. A
comparative study of serum protein-bound sialic acid in
benign and malignant prostatic growth: possible role of oxidative
stress in sialic acid homeostasis. Prostate Cancer Prostatic Dis
2007; 10: 356_9.
10 Belostotskaia LI, Nikitchenko IuV, Gomon N, Chaika LA,
Bondar' VV, Dziuba VN. [Effect of biologically active
substances of animal and plant origin on prooxidant-antioxidant
balance in rats with experimental prostatic hyperplasia.] Eksp
Klin Farmakol 2006; 4: 66_8.
11 Jonas A, Rosenblat G, Krapf D, Bitterman W, Neeman I.
Cactus flower extracts may prove beneficial in benign
prostatic hyperplasia due to inhibition of 5alpha reductase activity,
aromatase activity and lipid peroxidation. Urol Res 1998; 26:
265_70.
12 Tam N, Gao Y, Leung YK, Ho SM. Androgenic regulation of
oxidative stress in the rat prostate: involvement of NADPH
oxidases and antioxidant defense machinery during prostatic
involution and regrowth. Pathology 2003; 163: 2513_22.
13 Siddiqui IA, Raisuddin S, Shukla Y. Protective effects of black
tea extract on testosterone induced oxidative damage in prostate.
Cancer Lett 2005; 227: 125_32.
14 Prasad S, Kalra N, Shujla Y. Modulatory effects of diallyl
sulfide against testosterone-induced oxidative stress in Swiss
albino mice. Asian J Androl 2006; 8: 719_23.
15 Pérez Y, Menéndez R, Mas R, González RM.
In vitro effect of D-004, a lipid extract of the fruit of the Cuban royal palm
(Roystonea regia), on prostate steroid 5 a reductase
activity.Curr Ther Res 2006; 67: 396_405.
16 Noa M, Arruzazabala ML, Carvajal D, Más
R, Molina V. Effect of D-004, a lipid extract from Cuban royal palm fruit,
on histological changes of prostate hyperplasia induced with
testosterone in rats. Int J Tissue React 2005; 32: 193_8.
17 Carbajal D, Arruzazabala ML, Mas R, Molina V, Rodríguez E,
González V. Effects of D-004, a lipid extract from Cuban Royal
palm fruit, on inhibiting prostatic hypertrophy induced with
testosterone or dihydrotestosterone in a rat model: a randomized,
controlled study. Curr Ther Res 2004, 65: 505_14.
18 Arruzazabala ML, Mas R, Carbajal D, Molina V. Effects of
D-004, a lipid extract from the Cuban royal palm fruit, on
in vitro and in vivo effects mediated by alpha-adrenoceptors in
rats. Drugs R D 2005, 6: 281_9.
19 Arruzazabala ML, Más R, Molina V, Noa M, Carbajal D.
Effect of D-004, a lipid extract from the fruits of Cuban royal
palm, on the atypical prostate hyperplasia induced with
phenylephrine in rats. Drug R D 2006; 7: 233_41.
20 Menéndez R, Más R, Pérez Y, González RM.
In vitro effect of D-004, a lipid extract of the ground fruits of the Cuban
royal palm (Roystonea regia), on rat microsomal lipid
peroxidation. Phytother Res 2007; 21: 89_95.
21 Menéndez R, Más R, Pérez Y, González RM, Jiménez S.
Estudio de los efectos de la administración oral de D-004
(50_800 mg/kg de peso) sobre la peroxidación lipídica en ratas. Rev
CNIC 2005; 36: 28_35.
22 Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in
animal tissues by thiobarbituric acid reaction. Anal Biochem
1979; 95: 351_8.
23 Markwell MA, Haas SM, Beiber LL, Tolbert NE. A
modification of the Lowry procedure to simplify protein
determination in membrane lipoprotein samples. Anal Biochem 1978;
87: 206_10.
24 Ruiz-Larrea MB, Leal AM, Liza A, Lacort M, de Groot H.
Antioxidant effects of stradiol and 2-hydroyestradiol on
iron-induced lipid peroxidation in rat liver microsomes. Steroids
1994; 59: 383_6.
25 Reznick AZ, Packer L. Oxidative damage to proteins:
spectrophotometric method for carbonyl assay. In: Packer L, editor.
Methods in Enzymology, vol 233. London: Academic Press;
1994: p357_63.
26 Carbajal D, Molina V, Más R, Arruzazabala ML. Therapeutic
effects of D-004, a lipid extract from Roystonea
regia fruits, on prostate hyperplasia induced in rats. Drugs Exp Clin Res
2005; 31: 193_7.
27 Arguelles S, Garcia S, Maldonado M, Machado A, Ayala A.
Do the serum oxidative stress biomarkers provide a reasonable
index of the general oxidative stress status? Biochim Biophys
Acta 2004; 1674: 251_9.
28 Hermans N, Cos P, De Meyer GR. Study of potential
systemic oxidative stress animal models for the evaluation of
antioxidant activity: status of lipid peroxidation and fat-soluble
antioxidants. J Pharm Pharmacol 2007; 59: 131_6.
29 Aydin A, Arsova-Sarafinovska Z, Sayal A. Oxidative stress
and antioxidant status in non-metastatic prostate cancer and
benign prostatic hyperplasia. Clin Biochem 2006; 39: 176_9.
30 Hass MA, Nowak DM, Leonova E. Identification of
components of Prunus africana extract that inhibit lipid peroxidation.
Phytomedicine 1999; 6: 379_88.
31 Pérez Y, Menéndez R, Más R, González RM. Study of plasma
levels, tissue distribution and excretion of radioactivity after
single oral administration of D-004, a lipid extract of
Roystonea regia fruit, supplemented with
3H-oleic acid. Curr Ther Res Clin Exp 2006; 67: 406_12.
|